In Kenya, a person diagnosed with depression at a public clinic is likely to walk out with a prescription for amitriptyline—a tricyclic antidepressant first approved in the 1960s. The country's national guidelines, updated in 2021, recommend selective serotonin reuptake inhibitors (SSRIs) like fluoxetine or sertraline as first-line therapy. But those drugs are rarely stocked in government facilities. The gap between what guidelines say and what clinics dispense is not a minor oversight. It shapes the real-world treatment that hundreds of thousands of Kenyans receive.

Guidelines Say SSRIs, but Clinic Shelves Tell a Different Story

Kenya's Ministry of Health adopted the WHO Mental Health Gap Action Programme (mhGAP) guidelines, which list SSRIs as first-line for moderate to severe depression. The Kenya Essential Medicines List (KEML) includes fluoxetine, sertraline, and citalopram. Yet a 2023 survey of 47 public health facilities in four counties found that 89% stocked only amitriptyline among antidepressants. None stocked fluoxetine.

Amitriptyline has a narrower therapeutic index than SSRIs—the difference between an effective dose and a toxic one is small. It causes anticholinergic side effects such as dry mouth, constipation, blurred vision, and sedation. In overdose, it can cause cardiac arrhythmias and death. SSRIs, while not free of side effects, are generally safer in overdose and better tolerated over long-term use.

The mismatch is not a secret. Clinicians in public facilities report that they know the guidelines recommend SSRIs but cannot prescribe them because the pharmacy does not have them. A 2022 qualitative study from Kilifi County quoted a nurse saying, “We know fluoxetine is better, but we only have amitriptyline. So we prescribe what we have.”

Procurement decisions at the county and national level determine what reaches the shelf. The Kenya Medical Supplies Authority (KEMSA) buys antidepressants in bulk, and the choice has historically favored amitriptyline because of its low cost and multiple uses—it is also prescribed for neuropathic pain and insomnia. SSRIs are not interchangeable for those conditions.

Why Amitriptyline Persists Despite Outdated Status

Cost is the most frequently cited reason. A month's supply of generic amitriptyline costs roughly US$1–2 at public-sector prices, while a month of generic fluoxetine runs US$4–8. For a system where mental health receives less than 1% of the national health budget, the difference matters. Switching to SSRIs across all public facilities could increase the antidepressant drug budget by 30–50%, according to rough estimates by Kenyan health economists.

Supply chain factors also play a role. Amitriptyline is a WHO Essential Medicine and is produced by multiple manufacturers, including local suppliers. SSRI production is more concentrated, and Kenyan distributors often face stockouts of fluoxetine and sertraline. A 2024 report by the Kenya Pharmacy and Poisons Board noted that SSRI imports are less predictable than those for tricyclics.

Another factor is the lack of psychiatric input in procurement. In many counties, the drug selection committee includes no mental health specialist. A 2021 analysis of KEMSA procurement records found that amitriptyline orders were placed by non-specialist pharmacists who defaulted to the cheapest option. The same study noted that when psychiatrists were consulted, they consistently recommended adding SSRIs.

Global health funding patterns reinforce the status quo. Major donors like the Global Fund and PEPFAR focus on HIV, TB, and malaria—not mental health. The World Bank's pandemic preparedness funds have also bypassed mental health. Without external pressure or dedicated budgets, mental health remains a low priority in procurement.

Patient Experience: Side Effects Drive Non-Adherence

For the patient, the difference between amitriptyline and an SSRI is not abstract. A 2023 cohort study in Nairobi followed 150 patients started on amitriptyline for depression. At six weeks, 42% had stopped taking the drug. The most common reasons were sedation (reported by 61%), dry mouth (55%), and constipation (38%). Many patients said the side effects interfered with work or daily activities.

In rural Kilifi County, a separate interview-based study found that patients often stopped amitriptyline without telling their clinician. Some switched to herbal remedies. Others simply endured the depression rather than the side effects. One participant said, “The medicine made me sleep all day. I could not take care of my children. So I stopped.”

SSRIs are not side-effect-free. Fluoxetine can cause nausea, headache, and insomnia, especially in the first two weeks. But these effects are generally less disabling than the anticholinergic burden of amitriptyline. SSRIs also require fewer dose adjustments; amitriptyline must be titrated slowly to avoid toxicity, and many primary-care clinicians lack the training to manage this.

No formal monitoring system tracks real-world adherence to antidepressants in Kenyan public clinics. The Ministry of Health's District Health Information System (DHIS2) records the number of prescriptions but not whether patients fill them or continue taking them. This data gap means the scale of non-adherence is likely underestimated.

A 2022 Trial in Nairobi Shows Feasibility of Switching

In 2022, researchers at Kenyatta National Hospital published an open-label randomized trial comparing fluoxetine and amitriptyline in 200 adults with moderate to severe depression. The trial lasted 12 weeks. The fluoxetine group had a higher response rate—roughly 55% achieved at least a 50% reduction in Hamilton Depression Rating Scale scores, compared to about 40% in the amitriptyline group. Dropout due to side effects was lower in the fluoxetine arm (12% vs. 24%).

The trial also measured quality of life using the WHOQOL-BREF instrument. Fluoxetine patients reported better scores in the physical health and psychological domains. The cost of fluoxetine in the study was higher—about US$8 per month versus US$1.50 for amitriptyline—but still well under US$10 per month. The authors concluded that switching to fluoxetine was feasible in a hospital setting and likely cost-effective over a longer treatment horizon.

Critics of the trial note that it was open-label, meaning patients and clinicians knew which drug was being given, which could bias results. It was also conducted at a tertiary hospital with more resources than a typical rural clinic. The adherence rate in the fluoxetine arm was supported by weekly phone calls from study staff—a level of support not available in routine care.

Still, the trial provides some of the best available evidence from Kenya that SSRIs are both more effective and better tolerated. It also demonstrated that fluoxetine can be prescribed safely by non-specialists when given clear dosing protocols—a key point for scaling up.

Economic Barriers to Updating the Formulary

The main obstacle to adding SSRIs to the public formulary is not clinical evidence but economics. Kenya's total health expenditure per capita is roughly US$80, and mental health receives less than 1% of that. The annual antidepressant budget for a typical county hospital is around US$10,000–20,000. Switching to SSRIs could increase that to US$13,000–30,000—a significant jump for a line item that is already stretched.

Donor funding for mental health remains negligible. The World Bank's Global Financing Facility, which supports reproductive, maternal, and child health in Kenya, does not include mental health. The WHO's Mental Health Gap Action Programme provides technical assistance but not drug procurement. Without a dedicated funding stream, the cost of SSRIs falls entirely on the already strained county budgets.

Local production of generic SSRIs could lower prices. Kenya has a nascent pharmaceutical manufacturing sector, with companies like Universal Corporation Ltd. producing some generics. But SSRIs require more complex synthesis than tricyclics, and the domestic market is small. A 2023 feasibility study estimated that local production could cut the price of fluoxetine by 30–40%, but would require an initial investment of roughly US$2 million for equipment and quality certification.

There is also no organized patient advocacy pushing for better access to antidepressants. Mental health stigma remains high, and few patients or families lobby the Ministry of Health. The Kenya Psychiatric Association has issued statements calling for formulary reform, but without political pressure, the issue remains low on the agenda.

Community Health Workers as a Workaround

In response to the shortage of mental health specialists, Kenya has expanded task-shifting programs. Community health workers (CHWs) and nurses are trained to screen for depression using the PHQ-9 and to initiate treatment. But they are only allowed to prescribe drugs from the facility's existing stock—which is almost always amitriptyline.

Some NGO-run pilot projects have supplied fluoxetine directly. For example, a program in Makueni County, supported by the nonprofit BasicNeeds, provided fluoxetine to CHWs for a two-year period. Preliminary results showed improved adherence and symptom reduction compared to nearby clinics using amitriptyline. But when the project ended, the supply stopped.

Supervision is another challenge. CHWs are often supervised by a nurse who is supervised by a clinical officer—neither of whom may have psychiatric training. Dose adjustments for amitriptyline require careful monitoring of side effects, which is difficult when the supervisor is a phone call away. SSRIs, with their simpler dosing, would be easier to manage in this structure.

Patients in these programs report high trust in CHWs, who are often from the same community. But trust does not translate to access to preferred drugs. One CHW in Makueni said, “Patients ask for the medicine that does not make them sleepy. I have to tell them we only have the sleepy one.”

What Would Close the Gap? Small Steps and Advocacy

Updating the Kenya Essential Medicines List to include escitalopram or sertraline as mandatory stock items would be a first step. The list is revised every two years, and the next revision is due in 2025. The Kenya Psychiatric Association has submitted a proposal, but it is competing with requests for cancer drugs, antibiotics, and vaccines.

Bulk procurement through KEMSA could reduce SSRI prices. If KEMSA committed to a national tender for fluoxetine, it could negotiate volume discounts with Indian generic manufacturers. A 2024 analysis by the Health Ministry estimated that a national tender could bring the cost of fluoxetine down to US$3–4 per month—comparable to what some private clinics already pay.

Integration of mental health into primary care budgets is another lever. Currently, antidepressant procurement is often a separate line item that gets cut. If mental health were bundled into the general primary-care budget, it might receive more consistent funding. Some counties, like Nyeri, have already started this integration and report better availability of SSRIs.

Clinicians and patients need a formal voice in procurement decisions. Most county drug committees have no mental health representation. Adding a psychiatrist or a trained psychiatric nurse to each committee could shift choices toward evidence-based prescribing. Patient advocates, though rare, could also be included. Small changes in who sits at the table can change what ends up on the shelf.

None of these steps are easy or quick. The gap between guidelines and practice in Kenya is not unique—it mirrors similar mismatches in other low- and middle-income countries. But it is also not immutable. The evidence for SSRIs is clear, the feasibility has been demonstrated, and the cost is not prohibitive. What is missing is the political will to make mental health a procurement priority.

Adding Fluoxetine to Primary Care: A Pilot in Nyeri County

Nyeri County offers a rare example of successful formulary reform. In 2023, the county health department added fluoxetine to the essential medicines list for all primary care facilities, supported by a small budget increase from the county assembly. Nurses and clinical officers received a half-day training on SSRI dosing and side effect management. Within six months, fluoxetine accounted for roughly 40% of all antidepressant prescriptions in the county, and reports from facility in-charges indicated fewer complaints of sedation and dry mouth compared to amitriptyline.

The Nyeri experience shows that change is possible without large external funding. The additional cost per patient was estimated at US$3–5 per month, absorbed by reallocating funds from less-used medications. However, the pilot faced challenges: some patients initially refused fluoxetine because they had heard that amitriptyline was “stronger” (a common belief linked to its sedative effect). Nurses had to spend extra time explaining that the newer drug was equally effective with fewer side effects. Training also needed reinforcement—after three months, a follow-up survey found that 20% of nurses had reverted to prescribing amitriptyline as first-line, often due to habit or patient demand.

Despite these hurdles, the Nyeri pilot demonstrates that local political will and modest budget reallocation can begin to close the guideline-practice gap. It also highlights the need for sustained education and patient engagement.

Counter-Arguments: Is Amitriptyline Really That Bad?

Some clinicians argue that amitriptyline remains a reasonable option for depression, especially in settings where monitoring is minimal. They point out that the drug is effective—meta-analyses show tricyclics are as effective as SSRIs in reducing depressive symptoms, at least in the short term. And for patients with comorbid insomnia or chronic pain, amitriptyline's sedative and analgesic properties can be advantageous. In a context where many patients have untreated pain or sleep disturbances, a single drug that addresses both depression and these symptoms might simplify treatment.

However, this argument overlooks the tolerability advantage of SSRIs. In the same meta-analyses, dropout rates due to side effects are consistently lower with SSRIs. For a primary care setting where follow-up is irregular, a drug that patients are more likely to continue taking is preferable. Moreover, the analgesic dose of amitriptyline (typically 10–50 mg) is lower than the antidepressant dose (often 75–150 mg), and using it for depression at higher doses increases the anticholinergic burden. Clinicians who prescribe amitriptyline for both indications may inadvertently use subtherapeutic doses for depression or unsafe doses for pain.

Another counter-argument is that the cost difference is too large for a system with many competing priorities. A 2024 cost-effectiveness analysis from the University of Nairobi modeled the incremental cost per disability-adjusted life year (DALY) averted when switching from amitriptyline to fluoxetine in primary care. The estimate was roughly US$150–250 per DALY averted—well below Kenya's GDP per capita (about US$2,000), which is the WHO threshold for “very cost-effective.” The analysis assumed a 15% improvement in adherence with fluoxetine, based on the Nairobi trial. Even with conservative assumptions, the intervention was cost-effective. The barrier is not cost-effectiveness but upfront budget impact: the additional US$3–5 per patient per month must be found within a fixed county health budget.

Finally, some argue that improving adherence to amitriptyline—through better patient education, dose titration, and side effect management—would be cheaper than switching drugs. While this is theoretically possible, it requires more clinician time and training, both of which are scarce. In practice, many patients receive a standard dose of amitriptyline 25–50 mg at night with no follow-up. Enhancing this process would likely require as much investment as switching to SSRIs, without the benefit of a safer side effect profile.

Conclusion: The Path Forward

The gap between Kenya's depression guidelines and the reality of clinic shelves is a symptom of broader neglect of mental health in health systems. It can be closed through a combination of policy changes, budget reallocation, and advocacy. The Nyeri pilot shows that local action is possible. The evidence from the Nairobi trial and cost-effectiveness analyses supports the switch. What remains is the political will to prioritize mental health in procurement decisions. For the hundreds of thousands of Kenyans living with depression, that shift cannot come soon enough.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional.